Huseyin Naci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5837821/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Study design, result posting, and publication of late-stage cardiovascular trials. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 277-288.	4.0	5
2	The Cyprus Women's Health Research (COHERE) initiative: normative data from the SF-36v2 questionnaire for reproductive aged women from the Eastern Mediterranean. Quality of Life Research, 2022, 31, 2011-2022.	3.1	3
3	Ultraexpensive gene therapies, industry interests and the right to health: the case of onasemnogene abeparvovec in Brazil. BMJ Global Health, 2022, 7, e008637.	4.7	1
4	Use of adherence monitoring in drug contracts tied to outcomes: put patients first. BMJ, The, 2022, 376, e062188.	6.0	1
5	Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. Lancet Oncology, The, 2022, 23, 514-520.	10.7	22
6	Pharmacy interventions on COVID-19 in Europe: Mapping current practices and a scoping review. Research in Social and Administrative Pharmacy, 2022, 18, 3338-3349.	3.0	20
7	Coverage of New Drugs in Medicare Part D. Milbank Quarterly, 2022, 100, 562-588.	4.4	3
8	Postâ€Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014. Clinical Pharmacology and Therapeutics, 2022, 112, 846-852.	4.7	2
9	NITRATE-CIN Study: Protocol of a Randomized (1:1) Single-Center, UK, Double-Blind Placebo-Controlled Trial Testing the Effect of Inorganic Nitrate on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography for Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 303-309.	2.0	5
10	Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. JAMA Internal Medicine, 2021, 181, 490.	5.1	32
11	Communication of Survival Data in US Food and Drug Administration–Approved Labeling of Cancer Drugs. JAMA Internal Medicine, 2021, 181, 1521.	5.1	5
12	The Coverage in England of US-Approved Cancer Drugs—Reply. JAMA Internal Medicine, 2021, 181, 1263.	5.1	0
13	Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. BMJ, The, 2021, 374, n2191.	6.0	19
14	Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval. JAMA Internal Medicine, 2021, 181, 1673.	5.1	16
15	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 2021, 181, 1596-1604.	5.1	14
16	Putting patients first in medicines regulation?. BMJ, The, 2021, 375, n2883.	6.0	0
17	European Medicines Agency's Priority Medicines Scheme at 2ÂYears: An Evaluation of Clinical Studies Supporting Eligible Drugs. Clinical Pharmacology and Therapeutics, 2020, 107, 541-552.	4.7	9
18	Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. Heart Failure Reviews, 2020, 25, 161-171.	3.9	8

#	Article	IF	CITATIONS
19	Infographic. How does exercise treatment compare with antihypertensive medications?. British Journal of Sports Medicine, 2020, 54, 746-747.	6.7	1
20	Inappropriate use of progression-free survival in cancer drug approvals. BMJ, The, 2020, 368, m770.	6.0	6
21	Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States. Milbank Quarterly, 2020, 98, 1219-1256.	4.4	37
22	Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies. Pharmacoeconomics, 2020, 38, 1297-1308.	3.3	23
23	Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. BMJ, The, 2020, 371, m3869.	6.0	16
24	Specialty Drugs — A Distinctly American Phenomenon. New England Journal of Medicine, 2020, 382, 2179-2181.	27.0	7
25	Generating comparative evidence on new drugs and devices after approval. Lancet, The, 2020, 395, 998-1010.	13.7	52
26	Generating comparative evidence on new drugs and devices before approval. Lancet, The, 2020, 395, 986-997.	13.7	59
27	Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. Lancet, The, 2020, 395, 926-928.	13.7	6
28	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 2020, 108, 350-357.	4.7	41
29	NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances. International Journal of Technology Assessment in Health Care, 2020, 36, 426-433.	0.5	7
30	Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals. International Journal of Technology Assessment in Health Care, 2020, 36, 311-316.	0.5	3
31	The Supercar Stays in the Garage: Factors Preventing Indirect Comparisons of Novel Medicines Targeting the Same Condition. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 333-334.	0.9	0
32	Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs. Value in Health, 2020, 23, 319-327.	0.3	15
33	Prognostic Significance of Left Ventricular Noncompaction. Circulation: Cardiovascular Imaging, 2020, 13, e009712.	2.6	74
34	Recent Trends and Potential Drivers of Non-invasive Cardiovascular Imaging Use in the United States of America and England. Frontiers in Cardiovascular Medicine, 2020, 7, 617771.	2.4	15
35	Study design, result reporting and publication of late-stage cardiovascular trials. European Heart Journal, 2020, 41, .	2.2	0
36	New agreement on branded drugs for the NHS. BMJ: British Medical Journal, 2019, 364, l266.	2.3	7

#	Article	IF	CITATIONS
37	Effectiveness of interventions for dementia in low- and middle-income countries: protocol for a systematic review, pairwise and network meta-analysis. BMJ Open, 2019, 9, e027851.	1.9	5
38	Cyprus Women's Health Research (COHERE) initiative: determining the relative burden of women's health conditions and related co-morbidities in an Eastern Mediterranean population. BMC Women's Health, 2019, 19, 50.	2.0	4
39	Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease. Npj Digital Medicine, 2019, 2, 17.	10.9	5
40	Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection. Medical Decision Making, 2019, 39, 264-277.	2.4	11
41	Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support. Medical Decision Making, 2019, 39, 239-252.	2.4	8
42	Can we rely on non-randomised studies? Findings from a meta-epidemiological review. European Journal of Public Health, 2019, 29, .	0.3	0
43	Comparative efficacy and complication rates after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE Group. BMJ Open, 2019, 9, e028008.	1.9	3
44	Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ: British Medical Journal, 2019, 366, 15221.	2.3	117
45	Comparative fertility and pregnancy outcomes after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE group. BMJ Open, 2019, 9, e028009.	1.9	9
46	How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure. British Journal of Sports Medicine, 2019, 53, 859-869.	6.7	207
47	A review of NICE appraisals of pharmaceuticals 2000–2016 found variation in establishing comparative clinical effectiveness. Journal of Clinical Epidemiology, 2019, 105, 50-59.	5.0	25
48	Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance. Applied Health Economics and Health Policy, 2019, 17, 189-211.	2.1	8
49	The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany. European Journal of Health Economics, 2018, 19, 223-228.	2.8	9
50	Planning a future randomized clinical trial based on a network of relevant past trials. Trials, 2018, 19, 365.	1.6	31
51	The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. Clinical Trials, 2018, 15, 219-229.	1.6	38
52	The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation. Clinical Trials, 2018, 15, 243-246.	1.6	10
53	A Cost-Utility Analysis of Cryoballoon Ablation versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. Journal of Atrial Fibrillation, 2018, 11, 2069.	0.5	2
54	Avoidable costs of stenting for aortic coarctation in the United Kingdom: an economic model. BMC Health Services Research, 2017, 17, 258.	2.2	1

#	Article	IF	CITATIONS
55	Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval. Milbank Quarterly, 2017, 95, 261-290.	4.4	52
56	Impact of the International Recommendations for Electrocardiographic Interpretation on Cardiovascular ScreeningÂin Young Athletes. Journal of the American College of Cardiology, 2017, 70, 805-807.	2.8	44
57	What to do (or not to do) when randomization is not possible. Journal of Heart and Lung Transplantation, 2017, 36, 1174-1177.	0.6	6
58	Health policy in times of austerity—A conceptual framework for evaluating effects of policy on efficiency and equity illustrated with examples from Europe since 2008. Health Policy, 2017, 121, 947-954.	3.0	22
59	Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. JAMA - Journal of the American Medical Association, 2017, 318, 626.	7.4	148
60	Accelerated access to new drugs and technologies. BMJ: British Medical Journal, 2017, 359, j5387.	2.3	6
61	Evidence Required for Drugs Granted Accelerated Approval—Reply. JAMA - Journal of the American Medical Association, 2017, 318, 2493.	7.4	Ο
62	Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ: British Medical Journal, 2017, 359, j4530.	2.3	423
63	History Bias, Study Design, and the Unfulfilled Promise of Pay-for-Performance Policies in Health Care. Preventing Chronic Disease, 2016, 13, E82.	3.4	22
64	Bicuspid aortic valve disease: systematic review and meta-analysis of surgical aortic valve repair. Open Heart, 2016, 3, e000502.	2.3	10
65	Economic evaluation of mental health interventions: an introduction to cost-utility analysis. Evidence-Based Mental Health, 2016, 19, 49-53.	4.5	27
66	Communication of Treatment Rankings Obtained From Network Meta-Analysis Using Data Visualization. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 605-608.	2.2	4
67	Cost Implications of Using Different ECGÂCriteria for Screening YoungÂAthletesÂin the United Kingdom. Journal of the American College of Cardiology, 2016, 68, 702-711.	2.8	59
68	Balloon Dilatation and Stenting for Aortic Coarctation. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	40
69	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal, 2016, 37, 747-754.	2.2	62
70	Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment. Medical Decision Making, 2015, 35, 859-871.	2.4	44
71	Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 58-65.	4.0	6
72	How Good Is "Evidence―from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?. Annual Review of Pharmacology and Toxicology, 2015, 55, 169-189.	9.4	58

#	Article	IF	CITATIONS
73	Evaluation of Wellness Determinants and Interventions by Citizen Scientists. JAMA - Journal of the American Medical Association, 2015, 314, 121.	7.4	71
74	From "retailers―to health care providers: Transforming the role of community pharmacists in chronic disease management. Health Policy, 2015, 119, 628-639.	3.0	294
75	Capsule Commentary on Ott et al., Do Statins Impair Cognition? A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of General Internal Medicine, 2015, 30, 347-347.	2.6	0
76	Why the drug development pipeline is not delivering better medicines. BMJ, The, 2015, 351, h5542.	6.0	34
77	Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. British Journal of Sports Medicine, 2015, 49, 1414-1422.	6.7	89
78	Rethinking the appraisal and approval of drugs for type 2 diabetes:. BMJ, The, 2015, 351, h5260.	6.0	13
79	QALYs in cost-effectiveness analysis: an overview for cardiologists. Heart, 2015, 101, 1868-1873.	2.9	25
80	Preventing cardiovascular events with empagliflozin: at what cost?. Lancet Diabetes and Endocrinology,the, 2015, 3, 931.	11.4	3
81	An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review. PLoS ONE, 2015, 10, e0121715.	2.5	28
82	No evidence of industry sponsorship bias in statin trials. BMJ, The, 2014, 349, g6579-g6579.	6.0	6
83	Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ, The, 2014, 349, g5741-g5741.	6.0	55
84	Medication Affordability Gains Following Medicare Part D Are Eroding Among Elderly With Multiple Chronic Conditions. Health Affairs, 2014, 33, 1435-1443.	5.2	30
85	Regulators Should Better Leverage Effectiveness Standards to Enhance Drug Value. Pharmacotherapy, 2014, 34, 1005-1011.	2.6	0
86	Evidence-Based Prescribing. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 787-792.	2.2	27
87	Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Medicine, 2013, 11, 159.	5.5	427
88	Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. European Journal of Preventive Cardiology, 2013, 20, 658-670.	1.8	58
89	Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. European Journal of Preventive Cardiology, 2013, 20, 641-657.	1.8	170
90	Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ, The, 2013, 347, f5577-f5577.	6.0	479

#	Article	IF	CITATIONS
91	Expanding the role of community pharmacists: Policymaking in the absence of policy-relevant evidence?. Health Policy, 2013, 111, 135-148.	3.0	78
92	Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses. Journal of Clinical Epidemiology, 2013, 66, 812-816.	5.0	15
93	Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 299-306.	0.5	30
94	Comparative Tolerability and Harms of Individual Statins. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 390-399.	2.2	236
95	Improving health care services in Northern Cyprus: a call for research and action. European Journal of Public Health, 2012, 22, 754-755.	0.3	9
96	The Economics of Health Care Delivery. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, 482-488.	1.8	14
97	Raising the bar for market authorisation of new drugs. BMJ, The, 2012, 345, e4261-e4261.	6.0	23
98	Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. Journal of Medical Economics, 2012, 15, 293-304.	2.1	9
99	Using Indirect Evidence to Determine the Comparative Effectiveness of Prescription Drugs: Do Benefits Outweigh Risks?. Health Outcomes Research in Medicine, 2011, 2, e241-e249.	0.6	10
100	Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ: British Medical Journal, 2011, 343, d4849-d4849.	2.3	41
101	Comparison of the metabolic and economic consequences of longâ€ŧerm treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a costâ€effectiveness analysis. Journal of Evaluation in Clinical Practice, 2010, 16, 744-755.	1.8	23
102	The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. Journal of Medical Economics, 2010, 13, 78-89.	2.1	47
103	The Critical Role Of Observational Evidence In Comparative Effectiveness Research. Health Affairs, 2010, 29, 1826-1833.	5.2	63
104	Distribution of road traffic deaths by road user group: a global comparison. Injury Prevention, 2009, 15, 55-59.	2.4	256
105	Productivity losses from road traffic deaths in Turkey. International Journal of Injury Control and Safety Promotion, 2008, 15, 19-24.	2.0	12